Engineered nuclease may renew CRISPR interest, Caszyme says
An engineered CRISPR-Cas12l nuclease could spark renewed interest in the CRISPR approach, Caszyme says.
The gene editing company published research in The CRISPR Journal detailing the performance characteristics of Asp2Cas12l M82, denoted as M82. The publication suggests M82 could be a compelling new tool for the wider genome editing and genetic medicines spheres.
M82 combines the intrinsic benefits associated with Cas12l nuclease – unique protein sequence & structure, generation of long protruding DNA ends after cleavage, and recognition of a C-rich PAM sequence – with high performance in human cells and other advantageous characteristics.
With a length of 867 amino acids, M82 was shown to be suitable for use with more size-constrained delivery systems like adeno-associated viruses. Simultaneously, researchers found M82 capable of achieving similar editing efficiencies to more-established CRISPR nucleases, with indel rates reaching 75-100%.
From a therapeutic perspective, M82 could prove a reliable tool for restoration of a gene, rather than just switching off a dysregulated gene.
“We are increasingly confident of Asp2Cas12l M82’s ability to stand out as a tool of choice in the CRISPR editing space,” said Caszyme Co-Founder and CEO, Dr Giedrius Gasiūnas.
“Reliable, precise and adaptable, M82 is suitable for a wide range of therapeutic applications.
“It is no secret that the CRISPR space has faced challenges and concerns in recent years – as with all gene editing technologies – however, we are confident in M82’s ability to create headroom for scientists to stand up and innovate within.
“Through our continued work exploring novel Cas systems, Caszyme is focused on advancing technologies that move beyond promise and into practical use, helping to translate genome editing into real-world treatments for patients.”
